Jinhyuk Lee
A natural product oral therapeutic for Alzheimer's, positioned as disease-modifying.
Sponsored researchIn-development
Get the Discover digest
Receive a weekly email digest of the latest neurology and neurological disease solutions added by the network.Discover innovations in neurology and neurological disease
Get the Discover digest
Receive a weekly email digest of the latest neurology and neurological disease solutions added by the network.Browse 570 solutions in neurology & neurological disease on the Halo network
Updated Nov 2, 2026
Neurology covers the drugs, delivery routes and measurement tools aimed at the brain, the spinal cord and the nerves. On Halo, the solutions cover alzheimer's therapeutics, crossing the blood-brain barrier, neuroinflammation targets, and multiple sclerosis and myelin. Sign up to search the full network and post your specific need.
Alzheimer's therapeutics
Jinhyuk Lee
VJ
University of California, Los Angeles
An orally bioavailable, brain-permeable molecule that raises soluble APP alpha.
Co-developmentIn-development
Crossing the blood-brain barrier
TS
University of Kansas
Cadherin peptides that open the blood-brain barrier enough to let a peptide drug through.
In-development
AK
Ben-Gurion University of the Negev
Uses light-induced mechanical force to open the barrier transiently, with no chemistry.
In-development
Neuroinflammation targets
PA
CUNY Graduate School and University Center
Modulates the integrated stress response in named brain cell types and not the whole tissue.
Sponsored researchIn-development
AK
University of Copenhagen
Whole-brain spatial transcriptomics mapping distinct microglial activation states.
Sponsored researchIn-development
Multiple sclerosis and myelin
JH
ELOVL6 inhibition promotes remyelination and lowers neuroinflammation in MS models.
Sponsored researchIn-development
NP
University of South Florida
A small molecule targeting the long non-coding RNA GAS5 to cut neuroinflammation and tau.
Sponsored researchIn-development
Neuropathic pain
Jian Guan
The cGP Lab Ltd · Startup
An oral natural ingredient aimed at the sensory dysfunction of peripheral neuropathy.
Sponsored researchIn-development
DY
Stanford University
An over-the-counter DMSO topical for neuropathic pain.
In-development
Disease models and screening
GA
Ben-Gurion University of the Negev
A low-dose rotenone mouse model of mitochondrial dysfunction that reproduces bipolar disorder-like behavior.
In-development
XQ
University of California, San Diego
Antisense oligonucleotides aimed at the APP-Rab5 axis to correct faulty autophagy in Down syndrome.
In-development
You're viewing a preview of neurology and neurological disease solutions on Halo.
Sign up free to search the full network and post your specific need.
Already have an account?
Who is working on neurology & neurological disease
Organizations in neurology & neurological disease
Universities, startups, and suppliers with solutions in neurology and neurological disease.
Neurology and neurological disease organizations
Innovators in neurology & neurological disease
Researchers and inventors advancing neurology and neurological disease.
Neurology and neurological disease expertsAbout neurology & neurological disease
Neurology on Halo is shaped by one obstacle: almost nothing reaches the brain unaided. A large share of the work is about crossing the blood-brain barrier, and much of the rest treats neurological disease as inflammation. On Halo it spans 7 groups, including alzheimer's therapeutics, crossing the blood-brain barrier, and neuroinflammation targets.
Stage of development. Work on neurology & neurological disease on Halo comes mostly from university programs. 74% are past proof of concept (TRL 4 or higher). Indiana University has the most, followed by University of Illinois Chicago. Co-development and sponsored research are the usual partnering routes, and about 54% of the solutions that state terms offer licensing.
Three trends in neurology and neurological disease on Halo
The barrier is the problem. Five separate approaches exist only to get a molecule into the brain: cadherin peptides that loosen the junctions, light-induced mechanical opening, a lipid-polymer hybrid particle, vesicles aimed at microglia, and an in-vivo assay for scoring whether a candidate arrives at all. The therapy is often downstream of the delivery.
Microglia as the target. Four programs treat the immune cell and not the neuron. One maps microglial activation states across the whole brain, another screens against microglial ferroptosis, a third pushes the niacin receptor HCAR2 toward neuroprotection in tau disease. The neuron is what gets protected, not what gets dosed.
Remyelination as a goal in its own right. The multiple sclerosis solutions are not immunosuppressants. ELOVL6 inhibition promotes remyelination directly, a small molecule targets the long non-coding RNA GAS5, and reduced GALC activity in adult white matter is treated as a druggable vulnerability. Repair and not restraint.
515organizations
570solutions listed
68%from university labs
74%past proof of concept
Frequently asked questions
What is neurology and neurological disease?
Neurology covers the drugs, delivery routes and measurement tools aimed at the brain, the spinal cord and the peripheral nerves. It spans methods for crossing the blood-brain barrier, neuroinflammation targets, remyelination in multiple sclerosis, non-opioid neuropathic pain, and the models and instruments used to measure any of it. Pharmaceutical developers and academic neuroscience groups are active in it.
What are examples of neurology and neurological disease?
Five examples of neurology and neurological disease solutions on Halo include:
- A natural product oral therapeutic for Alzheimer's, positioned as disease-modifying. (chongnoi H&D)
- Cadherin peptides that open the blood-brain barrier enough to let a peptide drug through. (University of Kansas)
- Modulates the integrated stress response in named brain cell types and not the whole tissue. (CUNY Graduate School and University Center)
- ELOVL6 inhibition promotes remyelination and lowers neuroinflammation in MS models. (Hasselt University)
- An oral natural ingredient aimed at the sensory dysfunction of peripheral neuropathy. (The cGP Lab Ltd)
Which companies and suppliers are developing neurology and neurological disease?
There are 515 organizations with neurology and neurological disease solutions on Halo, 140 of them universities and research institutions. Among them are chongnoi H&D, University of California, Los Angeles, and University of Kansas. Most offer co-development or sponsored research. Sign up to see every organization working in the area and to send them your specific need.
How do I find neurology and neurological disease research partners?
Browsing neurology and neurological disease solutions on Halo is free. Sign up to search the full network and save the ones you want. Post your specific need to get exact matches. Organizations reply directly on the platform.
What are R&D teams looking for in neurology and neurological disease?
Over the past 12 months, R&D teams on Halo have posted these neurology and neurological disease needs:
Related medicine research areas
Confirm digest type